CD8A and neoplasm: These inhibitors can inhibit the progression of tumor metastasis and angiogenesis and dramatically improve the survival status and immune function of CD8+ T cells by increasing the antigen‐presenting ability of DCs, inhibiting PPAR signaling, decreasing the expression of Tregs, and upregulating PD‐1 expression [257].